SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow dips below year-ago levels
Q3 FY2026 financing cash flow of $2.31M fell 91.2% year over year, behind the +118.3% change in trailing-twelve-month financing cash flow. Sequentially, it fell 94.1% from the prior quarter. Over 3 fiscal years it compounded at +53.0% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -91.2% toward the trailing-twelve-month pace of +118.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 86.3M USD
- Year-over-year change
- +84.6%
- 4-year CAGR
- +63.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 86.3M | +84.6% |
| FY2024 | 2024-12-31 | 46.76M | +109.5% |
| FY2023 | 2023-12-31 | 22.32M | -7.3% |
| FY2022 | 2022-12-31 | 24.08M | +99.4% |
| FY2021 | 2021-12-31 | 12.07M | — |
Financing Cash Flow vs competitors
How SLS compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +118.3% is the 8th highest of 11, against a peer median of +787.1%.
- Over three fiscal years its annual growth of +53.0% compares with a peer median of +212.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥2.54B CNY | +707.0% | +60.1% | 454.8% |
| LTM Sep 2026 | $436.09M USD | +91.6% | +2614.9% | — | |
| LTM Mar 2026 | $316.04M USD | +699.2% | +326.7% | 2659.6% | |
| LTM Jun 2026 | $275.24M USD | +867.1% | — | 4.7% | |
| LTM Aug 2026 | $261.21M USD | +28.6% | +26.8% | 37.2% | |
| LTM Mar 2026 | $251.18M USD | +3158.7% | +6.2% | — | |
| LTM Mar 2026 | $126.91M USD | +1085.3% | +379.4% | 364.0% | |
| LTM Sep 2026 | $117.69M USD | +118.3% | +53.0% | — | |
| LTM Mar 2026 | $69.59M USD | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $24.66M USD | +9371.4% | +212.3% | 147.5% | |
| LTM Mar 2026 | $4.82M USD | -98.6% | -32.6% | 2.1% | |
| Peer median (excluding SLS) | — | +787.1% | +212.3% | 95.9% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| Deferred Income Tax | (239K) | (457K) | 0 | 0 | 0 |
| Stock-Based Compensation | 1.01M | 1.73M | 1.39M | 1.56M | 1.96M |
| Change in Working Capital | (7.62M) | 5.64M | 3.35M | (6.65M) | (4.08M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.51M) | 1.21M | 2.3M | (2.14M) | (535K) |
| Other Working Capital | (5.1M) | 4.43M | 1.04M | (4.51M) | (3.54M) |
| Other Non-Cash Items | 248K | 10.13M | (36.67M) | (30.95M) | 597K |
| Operating Cash Flow | (26.02M) | (23.81M) | (31.41M) | (35.4M) | (28.39M) |
| Capital Expenditures | 0 | (4.5M) | (5.5M) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (4.5M) | (5.5M) | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 9.01M | 23.99M | 22.23M | 46.16M | 86.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.07M | 85K | 90K | 594K | (527K) |
| Financing Cash Flow | 12.07M | 24.08M | 22.32M | 46.76M | 86.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (13.95M) | (4.23M) | (14.6M) | 11.36M | 57.91M |
| Free Cash Flow | (26.02M) | (28.31M) | (36.91M) | (35.4M) | (28.39M) |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.